Blueprint Medicines Corp. (BPMC) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Loading...

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

How to use About us Blog

|

|

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

How to use About us Blog

Follow our journey and product updates

Product

Research a topic Stock screener Find companies Search for securities Load an existing portfolio Backtest

Learn

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices Build investment strategies with crypto

Company

How to use About us Blog

Team Research

There is currently no saved research for this page.

Blueprint Medicines Corp. (BPMC)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Company performance

Add to research

Current Price

as of Jun 18, 2025

$128.12

P/E Ratio

N/A

Market Cap

$8.29B

Description

Add to research

Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Metrics

Add to research

Overview

HQCambridge, MA
SectorHealth Technology
IndustryBiotechnology
TickerBPMC
Price$128.12-0.09%

Trading Information

Market cap$8.29B
Float96.33%
Average Daily Volume (1m)5,999,200
Average Daily Volume (3m)2,668,632
EPS-$2.46

Company

Revenue$562.12M
Rev growth (1yr)55.45%
Net income$0.50M
Gross margin95.14%
EBITDA margin-24.51%
EBITDA-$36.63M

EV$6.03B
EV/Revenue10.72
P/EN/A
P/S15.16
P/B24.18
Debt/Equity208.50

Documents

Add to research

SEC Filings

8-K (2025-06-02)

8-K (2025-05-01)

8-K (2025-02-13)

8-K (2025-01-13)

8-K (2024-12-18)

8-K (2024-10-30)

8-K (2024-08-01)

8-K (2024-06-14)

8-K (2024-05-24)

8-K (2024-05-02)

8-K (2024-04-25)

8-K (2024-02-22)

8-K (2024-02-15)

8-K (2024-01-08)

8-K (2023-10-26)

8-K (2023-08-25)

8-K (2023-08-02)

8-K (2023-06-30)

8-K (2023-06-27)

8-K (2023-05-25)

8-K (2023-05-22)

8-K (2023-05-04)

8-K (2023-03-28)

8-K (2023-02-27)

8-K (2023-02-23)

8-K (2023-02-16)

8-K (2023-02-10)

8-K (2023-01-09)

8-K (2023-01-06)

10-Q (2025-05-01)

10-Q (2024-10-30)

10-Q (2024-08-01)

10-Q (2024-05-02)

10-Q (2023-10-26)

10-Q (2023-08-02)

10-Q (2023-05-04)

10-K (2025-02-13)

10-K (2024-02-15)

10-K (2023-02-16)

Factset Street Account

StreetAccount Earnings Call Q&A Summary: Blueprint Medicines Q3 (2023-10-26T16:05:52Z)

EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Ayvakyt ($57.25, 0.00) (2023-11-10T13:03:43Z)

Blueprint Medicines upgraded to outperform from perform at Oppenheimer ($55.22, 0.00) (2023-10-27T10:39:37Z)

Blueprint Medicines reports Q3 EPS ($2.20) vs FactSet ($2.37) [17 est, ($2.69)-(2.13)] ($43.96, 0.00) (2023-10-26T11:10:07Z)

Earnings Calls

Earnings Report 2025Q1

Earnings Report 2024Q4

Earnings Report 2024Q3

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report (2023-10-26)

Earnings Report (2023-08-02)

Factset

Factset Business Description

Ask a question

New feature

Thematic Research

View all of your research in one place. Toggle open the floating actions menu and click Open research sidebar to view your saved research for the current page.